A Phase 3 interventional study of Budesonide/formoterol (Symbicort Turbuhaler) and Formoterol (Oxis Turbuhaler) in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 120 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-10-25.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 26th largest by enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2010, is one of 76 in phase 3, and was the 66th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 25 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,293 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
Drug: Budesonide/formoterol (Symbicort Turbuhaler)
Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily
Drug: Formoterol (Oxis Turbuhaler)
Drug page: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
2x160/4.5 microgram, inhalation, twice daily, 12 weeks
Also known as: Symbicort Turbuhaler
2 X 4.5 microgram, inhalation, twice daily, 12 weeks
Also known as: Oxis Turbuhaler
Pre-dose Forced Expiratory Volume in One Second (FEV1)
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization
1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization
Pre-dose Forced Vital Capacity (FVC)
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization
1 Hour Post-dose Forced Vital Capacity (FVC)
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
Time frame: Before randomization, 0, 4, 8 and 12 weeks after randomization
Percentage of Participants With Exacerbations
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.
Time frame: Daily during 12-week randomization treatment
Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment
Time frame: Daily during 12-week randomization treatment
Morning Peak Expiratory Flow(PEF)
The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Evening Peak Expiratory Flow (PEF)
The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Total Number of Day With Exacerbation
Total number of days with COPD exacerbation for each treatment group
Time frame: Daily during 12-week randomization treatment
Morning Forced Expiratory Volume in One Second (FEV1)
The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Evening Forced Expiratory Volume in One Second (FEV1)
The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score
The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.
Time frame: Daily during run-in period and daily during 12-week randomization treatment
Use of Rescue Medication
The change from Run-in period average to Treatment period average for each treatment group.
Time frame: Daily during run-in period and daily during 12-week randomization treatment
St George's Respiratory Questionnaire (SGRQ) Total Score
The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).
Time frame: Daily during run-in period and daily during 12-week randomization treatment
The first participant entered the study on 28 January 2010, and the last participant completed the study on 30 March 2011. A total of 1,710 participants were enrolled at 163 centres in 9 countries in Asia and Europe, and 1,293 participants who fulfilled the randomisation criteria were randomised.
| Milestone | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Started | 636 | 657 |
| Completed | 594 | 601 |
| Not completed | 42 | 56 |
| Withdrew: Withdrawal by subject | 15 | 26 |
| Withdrew: Adverse event | 21 | 28 |
| Withdrew: Eligibility criteria not fulfilled | 2 | 0 |
| Withdrew: Severe non-compliance to protocol | 3 | 2 |
| Withdrew: Due to deteriorating health condition | 1 | 0 |
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
| percentage of Baseline | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Pre-dose Forced Expiratory Volume in One Second (FEV1) | 104.6 (37.4 to 311.1) | 101.5 (35.1 to 218.5) |
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
| percentage of Baseline | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| 1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1) | 113.9 (55.5 to 336.3) | 111.2 (51.3 to 203.3) |
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
| percentage of Baseline | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Pre-dose Forced Vital Capacity (FVC) | 102.2 (57.3 to 313.8) | 100.9 (61.5 to 347.6) |
The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group
| percentage of Baseline | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| 1 Hour Post-dose Forced Vital Capacity (FVC) | 110.1 (62.0 to 262.7) | 108.7 (63.5 to 272.7) |
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.
| percentage of participants | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Percentage of Participants With Exacerbations | 11.9 | 16.9 |
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment
| event | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation | 93 | 151 |
The change from Run-in period average to Treatment period average for each treatment group
| Liter/minute (L/min) | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Morning Peak Expiratory Flow(PEF) | 4.29 ± 36.58 | -4.78 ± 30.61 |
The change from Run-in period average to Treatment period average for each treatment group
| Liter/minute (L/min) | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Evening Peak Expiratory Flow (PEF) | 2.55 ± 36.57 | -5.13 ± 31.52 |
Total number of days with COPD exacerbation for each treatment group
| days | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Total Number of Day With Exacerbation | 653 | 1098 |
The change from Run-in period average to Treatment period average for each treatment group
| Liter (L) | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Morning Forced Expiratory Volume in One Second (FEV1) | 0.0244 ± 0.2136 | -0.0312 ± 0.1712 |
The change from Run-in period average to Treatment period average for each treatment group
| Liter (L) | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Evening Forced Expiratory Volume in One Second (FEV1) | 0.0176 ± 0.2268 | -0.0324 ± 0.1724 |
Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group
| Nights with symptoms | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms | -0.20 ± 0.67 | -0.15 ± 0.66 |
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms | -0.34 ± 0.66 | -0.23 ± 0.65 |
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms | -0.24 ± 0.70 | -0.24 ± 0.68 |
The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.
| units on a scale | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score | -0.78 ± 1.62 | -0.61 ± 1.56 |
The change from Run-in period average to Treatment period average for each treatment group.
| inhalations/day | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| Use of Rescue Medication | -0.51 ± 1.51 | -0.26 ± 1.49 |
The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).
| units on a scale | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| St George's Respiratory Questionnaire (SGRQ) Total Score | -4.37 ± 14.544 | -2.90 ± 13.783 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort Turbuhaler (Experimental) | — | 43/636 (6.8%) | 61/636 (9.6%) |
| Oxis Turbuhaler (Active Comparator) | — | 45/657 (6.8%) | 66/657 (10%) |
| Event | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 24/636 | 28/657 |
| PNEUMONIARespiratory, thoracic and mediastinal disorders | 3/636 | 1/657 |
| INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASERespiratory, thoracic and mediastinal disorders | 1/636 | 3/657 |
| APPENDICITISInfections and infestations | 2/636 | 0/657 |
| PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders | 1/636 | 2/657 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 1/636 | 0/657 |
| PNEUMONIA BACTERIALInfections and infestations | 1/636 | 1/657 |
| BRONCHOPNEUMONIAInfections and infestations | 1/636 | 0/657 |
| POSTOPERATIVE ABSCESSInfections and infestations | 1/636 | 0/657 |
| ILEUSGastrointestinal disorders | 1/636 | 0/657 |
| Event | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) |
|---|---|---|
| NasopharyngitisInfections and infestations | 35/636 | 32/657 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 29/636 | 36/657 |
| Age Continuous(Years) | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) | Total |
|---|---|---|---|
| Mean | 64.5 (40 to 89) | 65.6 (40 to 87) | 65.1 (40 to 89) |
| Sex: Female, Male(Participants) | Symbicort Turbuhaler (Experimental) | Oxis Turbuhaler (Active Comparator) | Total |
|---|---|---|---|
| Female | 79 | 64 | 143 |
| Male | 557 | 593 | 1150 |
Showing the first 100 of 120 sites across 9 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Pulmonary Disease, Chronic Obstructive →